Literature DB >> 31281626

Practical clinical approach to the evaluation of hepatobiliary disorders in inflammatory bowel disease.

Afif Yaccob1, Amir Mari2.   

Abstract

Hepatobiliary disorders are frequent extraintestinal manifestations in inflammatory bowel disease (IBD) and may appear at any time point during the natural course of the disease. Conceptually, these manifestations can be categorised as: (1) disorders that have an association with IBD; (2) diseases directly and structurally related to intestinal inflammation; (3) diseases related to the adverse effects of IBD treatment; and (4) disorders stemming from the metabolic derangements caused by IBD. The clinical presentations of these disorders range from a mild transient elevation of liver enzymes to liver failure and death. Given this wide differential diagnosis and spectrum of severity, it is understandable that the evaluation of patients with IBD with a hepatobiliary abnormality is often challenging. In this review, we present a concise summary of the common hepatic manifestations seen in patients with IBD and focus on the relevant practical issues encountered by gastroenterologists caring for patients with IBD. A practical clinical approach to the evaluation of liver enzyme abnormalities in patients with IBD is provided based on the predominant enzyme elevation pattern (hepatocellular vs cholestatic), before presenting a working scheme for the prevention of hepatitis B virus (HBV) reactivation in patients with IBD receiving immunosuppressive medications. Finally, we specify several laboratory alterations seen in patients with IBD that can potentially interfere with the interpretation of liver function tests, before defining the specific circumstances when a referral for a hepatological consultation is required for further assessment.

Entities:  

Keywords:  hepatobiliary disease; ibd; liver function test

Year:  2018        PMID: 31281626      PMCID: PMC6583566          DOI: 10.1136/flgastro-2018-101037

Source DB:  PubMed          Journal:  Frontline Gastroenterol        ISSN: 2041-4137


  38 in total

Review 1.  AGA technical review on osteoporosis in gastrointestinal diseases.

Authors:  Charles N Bernstein; William D Leslie; Meryl S Leboff
Journal:  Gastroenterology       Date:  2003-03       Impact factor: 22.682

Review 2.  Drug-induced hepatotoxicity.

Authors:  William M Lee
Journal:  N Engl J Med       Date:  2003-07-31       Impact factor: 91.245

Review 3.  Skeletal morbidity in inflammatory bowel disease.

Authors:  R A van Hogezand; N A T Hamdy
Journal:  Scand J Gastroenterol Suppl       Date:  2006

4.  Chronic hepatitis B.

Authors:  Anna S F Lok; Brian J McMahon
Journal:  Hepatology       Date:  2007-02       Impact factor: 17.425

5.  Fracture risk is increased in Crohn's disease, but not in ulcerative colitis.

Authors:  P Vestergaard; K Krogh; L Rejnmark; S Laurberg; L Mosekilde
Journal:  Gut       Date:  2000-02       Impact factor: 23.059

6.  Low serum and bone vitamin K status in patients with longstanding Crohn's disease: another pathogenetic factor of osteoporosis in Crohn's disease?

Authors:  E J Schoon; M C Müller; C Vermeer; L J Schurgers; R J Brummer; R W Stockbrügger
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

7.  Abnormal hepatic biochemistries in patients with inflammatory bowel disease.

Authors:  Flavia D Mendes; Cynthia Levy; Felicity B Enders; Edward V Loftus; Paul Angulo; Keith D Lindor
Journal:  Am J Gastroenterol       Date:  2006-11-13       Impact factor: 10.864

8.  The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study.

Authors:  C N Bernstein; J F Blanchard; W Leslie; A Wajda; B N Yu
Journal:  Ann Intern Med       Date:  2000-11-21       Impact factor: 25.391

Review 9.  Review article: drug hepatotoxicity.

Authors:  C Y Chang; T D Schiano
Journal:  Aliment Pharmacol Ther       Date:  2007-05-15       Impact factor: 8.171

10.  Definitions, pathophysiology, and epidemiology of acute cholangitis and cholecystitis: Tokyo Guidelines.

Authors:  Yasutoshi Kimura; Tadahiro Takada; Yoshifumi Kawarada; Yuji Nimura; Koichi Hirata; Miho Sekimoto; Masahiro Yoshida; Toshihiko Mayumi; Keita Wada; Fumihiko Miura; Hideki Yasuda; Yuichi Yamashita; Masato Nagino; Masahiko Hirota; Atsushi Tanaka; Toshio Tsuyuguchi; Steven M Strasberg; Thomas R Gadacz
Journal:  J Hepatobiliary Pancreat Surg       Date:  2007-01-30
View more
  3 in total

Review 1.  Liver involvement in inflammatory bowel disease: What should the clinician know?

Authors:  Giuseppe Losurdo; Irene Vita Brescia; Chiara Lillo; Martino Mezzapesa; Michele Barone; Mariabeatrice Principi; Enzo Ierardi; Alfredo Di Leo; Maria Rendina
Journal:  World J Hepatol       Date:  2021-11-27

Review 2.  Hepatobiliary manifestations in inflammatory bowel disease: A practical approach.

Authors:  Paulina Núñez F; Fabiola Castro; Gabriel Mezzano; Rodrigo Quera; Diego Diaz; Lorena Castro
Journal:  World J Hepatol       Date:  2022-02-27

Review 3.  Liver manifestations and complications in inflammatory bowel disease: A review.

Authors:  Rui Gaspar; Catarina Castelo Branco; Guilherme Macedo
Journal:  World J Hepatol       Date:  2021-12-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.